文献速递预防保健、筛查与疫苗妇女保健儿童保健

孕期母亲mRNA新冠疫苗接种对婴儿德尔塔或奥密克戎感染及住院的影响:检测阴性设计研究

Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study.
PubMed 文献 · BMJ · 2023-02-08

该检测阴性设计研究纳入加拿大安大略省8809名6月龄以下婴儿,评估孕期母亲mRNA新冠疫苗接种对婴儿德尔塔和奥密克戎感染及住院的保护效果。结果显示,两剂次接种对德尔塔感染保护效果为95%,对奥密克戎感染为45%;三剂次对奥密克戎感染保护效果为73%。两剂次对奥密克戎的保护效果在孕晚期接种时最高,并随婴儿年龄增长而下降。

要点

  • 孕期两剂mRNA疫苗接种对婴儿德尔塔感染保护效果达95%,对奥密克戎为45%。
  • 三剂次接种对婴儿奥密克戎感染保护效果提升至73%,住院保护效果为80%。
  • 两剂次对奥密克戎的保护效果在孕晚期接种最高,且随婴儿月龄增长而减弱。

核心结论

  • 孕期接种两剂mRNA新冠疫苗对婴儿德尔塔和奥密克戎感染及住院具有保护效果,第三剂可增强对奥密克戎的保护。

研究设计与样本

  • 检测阴性设计研究,纳入加拿大安大略省2021年5月7日至2022年3月31日出生、6月龄以下并接受SARS-CoV-2检测的婴儿。

主要发现

  • 两剂次对婴儿德尔塔感染保护效果95%(95%CI 88%至98%),对德尔塔住院保护效果97%(95%CI 73%至100%)。
  • 两剂次对婴儿奥密克戎感染保护效果45%(95%CI 37%至53%),对奥密克戎住院保护效果53%(95%CI 39%至64%)。
  • 三剂次对婴儿奥密克戎感染保护效果73%(95%CI 61%至80%),对奥密克戎住院保护效果80%(95%CI 64%至89%)。
  • 两剂次对奥密克戎感染保护效果在孕晚期接种为53%(95%CI 42%至62%),高于孕早期47%(95%CI 31%至59%)和孕中期37%(95%CI 24%至47%)。
  • 两剂次对奥密克戎感染保护效果从出生至8周为57%(95%CI 44%至66%),16周后降至40%(95%CI 21%至54%)。

临床怎么用

  • 全科医生可告知孕期妇女,接种mRNA新冠疫苗可为其6月龄以下婴儿提供针对德尔塔和奥密克戎感染及住院的保护。
  • 孕晚期接种两剂次对婴儿奥密克戎感染保护效果较高,三剂次可进一步增强保护。
  • 婴儿8周后保护效果下降,需关注婴儿其他防护措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effectiveness of maternal mRNA covid-19 vaccination during pregnancy against delta and omicron severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and hospital admission in infants. DESIGN: Test negative design study. SETTING: Community and hospital testing in Ontario, Canada. PARTICIPANTS: Infants younger than six months of age, born between 7 May 2021 and 31 March 2022, who were tested for SARS-CoV-2 between 7 May 2021 and 5 September 2022. INTERVENTION: Maternal mRNA covid-19 vaccination during pregnancy. MAIN OUTCOME MEASURES: Laboratory confirmed delta or omicron infection or hospital admission of the infant. Multivariable logistic regression estimated vaccine effectiveness, with adjustments for clinical and sociodemographic characteristics associated with vaccination and infection. RESULTS: 8809 infants met eligibility criteria, including 99 delta cases (4365 controls) and 1501 omicron cases (4847 controls). Infant vaccine effectiveness from two maternal doses was 95% (95% confidence interval 88% to 98%) against delta infection and 97% (73% to 100%) against infant hospital admission due to delta and 45% (37% to 53%) against omicron infection and 53% (39% to 64%) against hospital admission due to omicron. Vaccine effectiveness for three doses was 73% (61% to 80%) against omicron infection and 80% (64% to 89%) against hospital admission due to omicron. Vaccine effectiveness for two doses against infant omicron infection was highest with the second dose in the third trimester (53% (42% to 62%)) compared with the first (47% (31% to 59%)) or second (37% (24% to 47%)) trimesters. Vaccine effectiveness for two doses against infant omicron infection decreased from 57% (44% to 66%) between birth and eight weeks to 40% (21% to 54%) after 16 weeks of age. CONCLUSIONS: Maternal covid-19 vaccination with a second dose during pregnancy was highly effective against delta and moderately effective against omicron infection and hospital admission in infants during the first six months of life. A third vaccine dose bolstered protection against omicron. Effectiveness for two doses was highest with maternal vaccination in the third trimester, and effectiveness decreased in infants beyond eight weeks of age.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Jorgensen SCJ, Hernandez A, Fell DB, et al. Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. BMJ. 2023. PMID: 36754426. doi:10.1136/bmj-2022-074035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。